Search results for "PCA3"

showing 3 items of 13 documents

Multiple Cutaneous Metastases in the Chest from Prostatic Carcinoma

2013

We report a case of multiple cutaneous metastases from prostate cancer. A 78-year-old man with an 8-year history of prostate cancer had multiple nodular lesions in the chest. Histologically, the lesion showed an abortive glandular lumina and tall columnar cells with abundant cytoplasm. Immunohistochemical staining for AE1:AE3 cytokeratin cocktail, prostate-specific antigen, and prostate-specific acid phosphatase was positive in tumor cells, confirming the diagnosis of cutaneous metastases from prostate cancer. We report this case because of the rarity of cutaneous metastases from prostatic adenocarcinoma in the chest region.

PCA3Pathologymedicine.medical_specialtyCutaneous metastases · Prostatic carcinoma · AE1:AE3 cytokeratin · Prostate-specific antigen · Prostate-specific acid phosphataseDermatologyPublished online: May 2013Prostatic carcinomaLesionProstate cancerCytokeratinAntigenlcsh:DermatologySettore MED/35 - Malattie Cutanee E VenereeCarcinomaMedicineAE1:AE3 cytokeratinProstate-specific acid phosphatasebusiness.industrylcsh:RL1-803Cutaneous metastasesmedicine.diseaseProstate-specific antigenProstate-specific antigenImmunohistochemistrymedicine.symptombusinessCase Reports in Dermatology
researchProduct

2015

Myoglobin (MB) is not only strongly expressed in myocytes, but also at much lower levels in different cancer entities. 40% of breast tumors are MB-positive, with the globin being co-expressed with markers of tumor hypoxia in a proportion of cases. In breast cancer, MB expression is associated with a positive hormone receptor status and patient prognosis. In prostate cancer, another hormone-dependent cancer type, 53% of tumors were recently shown to express MB. Especially in more aggressive prostate cancer specimen MB expression also correlates with increased patient survival rates. Both findings might be due to tumor-suppressing properties of MB in cancer cells. In contrast to muscle, MB tr…

PCA3Regulation of gene expressionProstate cancerMultidisciplinaryBreast cancerLNCaPCancer cellDNA methylationmedicineChromoplexyBiologymedicine.diseaseMolecular biologyPLOS ONE
researchProduct

Variations of components of the plasminogen activation system with the cell cycle in benign prostate tissue and prostate cancer

2001

Background: Components of the fibrinolytic system are involved in tumor cell invasion and metastasis. Previous investigations suggested a cell cycle-dependent expression of urokinase-type plasminogen activator (u-PA) in epithelial cells. In order to determine a correlation of cell cycle phases with the fibrinolytic system, we investigated the expression of u-PA, tissue-type plasminogen activator (t-PA), and plasminogen activator inhibitor type 1 (PAI-1) in normal and tumor-containing prostate extracts and analyzed a possible relationship with flow cytometry-determined proliferative activity of the samples. Cell cycle phases were correlated with fibrinolytic parameters in prostate tissue. Me…

PCA3medicine.medical_specialtyProliferation indexBiophysicsCell BiologyHematologyBiologyCell cyclemedicine.diseasePathology and Forensic MedicineMetastasischemistry.chemical_compoundProstate cancerEndocrinologymedicine.anatomical_structureEndocrinologychemistryProstatePlasminogen activator inhibitor-1Internal medicinemedicineCancer researchPlasminogen activatorCytometry
researchProduct